Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 3, pp 190–194 | Cite as

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370 147) 370 147

  • William R. Waud
  • Steadman D. HarrisonJr.
  • Carroll G. TempleJr
  • Daniel P. GriswoldJr.
Original Articles Cross-Resistance, P388 Leukemia, NSC 370147


Ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370 147) is a potent mitotic inhibitor, which has provided the basis for a candidate for clinical trial. As observed with clinically useful drugs, the development of clinical resistance to NSC 370 147 will probably be encountered. Information concerning resistance to NSC 370 147 should aid in the design of strategies for the opitmal clinical use of the drug. A P388 leukemia resistant to NSC 370 147 (P388/NSC 370 147) was isolated and its in vivo cross-resistance profile was determined. The P388/NSC 370 147 line was cross-resistant to vincristine but was not cross-resistant to doxorubicin, etoposide, cisplatin, melphalan, methotrexate, or 5-fluorouracil. This information plus other in vivo cross-resistance data [Waud et al. (1990) Cancer Res 50: 3239] suggests that NSC 370 147 may be useful in non-cross-resistant combinations with doxorubicin, melphalan, cisplatin, or methotrexate. The lack of cross-resistance of P388/NSC 370 147 to doxorubicin and etoposide shows that resistance to NSC 370 147 does not involve multidrug resistance and suggests that themdr1 gene is not involved in resistance to NSC 370 147.


Ethyl Hydrate Leukemia Cancer Research Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



dosage level producing 10% lethality

P388/NSC 370 147

P388 leukemia resistant to NSC 370 147


P388 reukemia sensitive to NSC 370 147




every 3 h for a total of three injections


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bowdon BJ, Waud WR, Wheeler GP, Hain R, Dansby L, Temple C Jr (1987) Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47: 1621Google Scholar
  2. 2.
    Hill BT, Whelan RDH, Bellamy AS (1984) Identification of differential drug responses and mechanism of resistance in vincristine-resistant cell lines developed either by exposure to the drug or to fractionated radiation. Cancer Treat Rev 11 [Suppl A]: 73Google Scholar
  3. 3.
    Horton JK, Houghton PJ, Houghton JA (1987) Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine andl-phenylalanine mustard. Cancer Res 47: 6288Google Scholar
  4. 4.
    Lloyd HH (1977) Application of tumor models toward the design of treatment schedules for cancer chemotherapy: In Drewinko B, Humphrey RM (eds) Growth kinetics and biochemical regulation of normal and malignant cells. Williams & Wilkins, Baltimore, p 455Google Scholar
  5. 5.
    Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther [A] 1: 411Google Scholar
  6. 6.
    Temple C Jr, Wheeler GP, Elliott RD, Rose JD, Kussner CL, Comber RN, Montgomery JA (1982) New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (I-deaza-7,8-dihydropteridines). J Med Chem 25: 1045Google Scholar
  7. 7.
    Temple C Jr, Wheeler GP, Elliott RD, Rose JD, Comber RN, Montgomery JA (1983) 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships. J Med Chem 26: 91Google Scholar
  8. 8.
    Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, harrison SD Jr, Griswold DP Jr (1990) Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370 147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239Google Scholar
  9. 9.
    Waud WR, Harrison SD Jr, Gilbert KS, Laster WR Jr, Griswold DP Jr (1991) Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol 27: 456Google Scholar
  10. 10.
    Wheeler GP, Bowdon BJ, Werline JA, Adamson DJ, Temple CG Jr (1982) Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilion)methyl]pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 18928). Cancer Res 42: 791Google Scholar
  11. 11.
    Wheeler GP, Bowdon BJ, Temple C Jr, Adamson DJ, Webster J (1983) Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-bpyrazines. Cancer Res 43: 3567Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • William R. Waud
    • 1
  • Steadman D. HarrisonJr.
    • 1
  • Carroll G. TempleJr
    • 2
  • Daniel P. GriswoldJr.
    • 1
  1. 1.Chemotherapy and Toxicology ResearchSouthern Research InstituteBirminghamUSA
  2. 2.Organic Chemistry ResearchSouthern Research InstituteBirminghamUSA

Personalised recommendations